GleamWall
中文EN

JUNS JUPITER NEUROSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1679628 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-86.1%
TTM EPS YoY71.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-673.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets171.6%
Debt / equity—
Current ratio0.49x
Interest coverage-39.17x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-253.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$13,942$24,245$18,652———$0—
Cost of revenue$4,334$3,181$4,362—————
Gross profit$9,608$21,064$14,290—————
R&D expense$3.89M$600,353$411,049$43,684$816,697$759,448$466,745$201,005
SG&A expense$1.91M$2.16M$1.57M$2.78M$1.48M$1.51M$1.07M$1.26M
Operating income-$5.80M-$2.74M-$1.96M-$2.81M-$2.30M-$2.26M-$1.54M-$1.46M
Interest expense$68,098$90,618$118,644$62,463$1,193$1,135$1,229$30,545
Net income-$7.22M-$2.27M-$2.06M-$2.58M-$2.29M-$2.25M-$1.53M-$1.53M
EPS (basic)-7.42-4.08-0.06—-5.04-5.09-0.05—
EPS (diluted)-7.42-4.08-0.06—-5.04-5.09-0.05—
Weighted avg. shares (diluted)973,633557,56735.26M—453,865442,41333.10M—
Balance sheet
Cash & equivalents$300,623$1.52M$2.36M$3.79M$723,797$1.88M$2.71M$3.77M
Receivables—$10,241—$2,637————
Inventory$130,957$135,290$148,068$159,790————
Current assets$1.26M$2.55M$3.41M$4.82M$1.63M$2.82M$3.61M$4.65M
Total assets$1.62M$3.72M$3.95M$5.56M$2.58M$3.97M$4.96M$6.20M
Current liabilities$2.59M$3.88M$6.73M$7.40M$2.52M$2.63M$1.89M$2.01M
Total liabilities$2.79M$4.08M$6.73M$7.40M$2.52M$2.63M$1.90M$2.03M
Shareholders' equity-$1.16M-$365,966-$2.78M-$1.83M$57,417$1.34M$3.06M$4.17M
Shares outstanding1.32M664,67036.28M459,28634.29M34.83M33.10M33.10M
Cash flow statement
Operating cash flow-$2.72M-$2.29M-$1.43M-$2.37M-$1.15M-$828,222-$1.06M-$3.70M
Financing cash flow$1.50M$1.45M$5,507————$7.47M
Stock-based compensation$551,874$490,997$500,992$463,241$1.07M$462,488$421,454$1.01M

Free plan shows the latest 8 periods; Pro shows all 15 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.